【医伴旅】欧盟批准首个JAK抑制剂:乌帕替尼用于治疗中度至重度特应性皮炎
撰稿: 医伴旅内容团队
原创文章,未经许可,请勿转载
商务合作请联系:13304614152
参考资料:
https://news.abbvie.com/news/press-releases/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-european-union-for-treatment-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis.html
赞 (0)